[Ip-health] CIPLA backed Stempeutics says China IP office grants process patent on stem cell ischemia candidate

Jamie Love james.love at keionline.org
Mon Apr 27 10:40:13 PDT 2015


India's Stempeutics says China IP office grants process patent on stem cell
ischemia candidate

April 27, 2015 | By EJ Lane

Cipla-backed Stempeutics, an Indian advanced clinical stage biotech company
based in Bangalore, said it is the first company in the world to be granted
a process patent by the State Intellectual Property Office of China for a
stem cell drug treatment based on pooling technology that could potentially
be used in the treatment of critical limb ischemia.

The process patent for its novel stem-cell based drug Stempeucel follows a
March designation by the European Medicines Agency has granted Advanced
Therapy Medicinal Product classification for the therapy that could be used
to treat patients with diabetes that suffer from the condition, the company

India and China have the highest number of diabetic patients in the world.

Stempeutics said it has submitted its application to the Drug Controller
General of India to obtain marketing authorization approval for Stempeucel.

Stempeutics has been intermittently in the news, but little is known about
the company. The State Intellectual Property Office (SIPO) website did have
the therapy listed under an application number.

It was founded by Manipal Education and Medical Group in 2006 and later
entered into a strategic alliance with Cipla in 2009 with a goal to develop
novel stem cell drugs addressing major unmet medical needs with an India
first global next approach.

It operates in a treatment space that includes efforts by Sanofi ($SNY) in
2010 and more recently Abbott Laboratories ($ABT) through the purchase of
IDEV Technologies.

- here's the Stempeutics release and the SIPO listing


Related Articles:

India's Stempeutics gets EMA advanced therapy designation for Stempeucel
Sanofi's critical limb ischemia drug flunks PhIII
Live From BIO 2010: A chat with Stempeutics

FiercePharmaAsia is the go-to source for news and analysis on the Asia
Pacific biopharma industry, with a sharp focus on drug and medtech
development, sales and marketing in China, Japan, India, Australia, Korea,
Singapore and more. Join biopharma leaders who get FiercePharmaAsia for
free. Sign up today!


James Love.  Knowledge Ecology International
KEI DC tel: +1.202.332.2670, US Mobile: +1.202.361.3040, Geneva Mobile:
+41.76.413.6584, twitter.com/jamie_love

More information about the Ip-health mailing list